Journal article icon

Journal article

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Abstract:

The clinical benefit of adding FMS-like tyrosine kinase-3 (FLT3)-directed small molecule therapy to standard first-line treatment of acute myeloid leukemia (AML) has not yet been established. As part of the UK AML15 and AML17 trials, patients with previously untreated AML and confirmed FLT3-activating mutations, mostly younger than 60 years, were randomly assigned either to receive oral lestaurtinib (CEP701) or not after each of 4 cycles of induction and consolidation chemotherapy. Lestaurtin...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1182/blood-2016-07-730648

Authors


More by this author
Role:
Author
ORCID:
0000-0002-6405-4441
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Department:
Unknown
Role:
Author
ORCID:
0000-0003-0166-0062
Expand authors...
UK Medical Research Council More from this funder
Publisher:
American Society of Hematology Publisher's website
Journal:
Blood Journal website
Volume:
129
Issue:
9
Pages:
1143-1154
Publication date:
2017-03-02
Acceptance date:
2016-11-06
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Pmid:
27872058
Source identifiers:
930218

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP